Midostaurin (RYDAPT®) is the only approved FLT3 inhibitor for newly diagnosed FLT3 mutation–positive AML and is administered in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation [19, 20]. Here, FLT3 is linked to acute myeloid leukemia.